Schizophrenia insight
July 24, 2014
AS PART of a multinational
collaborative research project,
over 100 locations in the human
genome associated with the risk
of developing schizophrenia have
been identified in the largest
genomic mapping exercise on any
psychiatric disorder yet.
Despite the pressing need for
treatment, medications currently
on the market treat only one of the
symptoms of psychosis and do not
address the debilitating cognitive
symptoms of schizophrenia, said
the researchers.
Schizophrenia affects
approximately one out of every
100 people worldwide and is
characterised by hallucinations,
paranoia, and a breakdown of
thought processes, often emerging
in the teens and early 20s.
About 80,000 samples were used
in this study with similar studies
on autism and bipolar disorder to
follow.
CLICK HERE to access the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 14